Previous 10 | Next 10 |
Yossi Borenstein to contribute his skills acquired through his 35 years of experience in the life science industry Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind sp...
jxfzsy/iStock via Getty Images Can-Fite Biopharma (CANF) has completed preparatory work for a phase 3 trial of namodenoson for hepatocellular carcinoma ("HCC") and will soon begin patient enrollment. The company has also received agreement from the FDA and the European Medicines Agency o...
FDA Granted Namodenoson Orphan Drug and Fast Track Status Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announc...
Can-Fite BioPharma (CANF) perks up 8% premarket after signing a development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats...
All pre-clinical, clinical, and regulatory development work to be conducted and financially covered by Vetbiolix Veterinary market has potential for a shorter path to regulatory approval and product revenues Can-Fite BioPharma Ltd . (NYSE American: CA...
Can-Fite BioPharma (CANF) announces that the Chinese National Intellectual Property Administration has issued a Notice of Allowance for its patent addressing the use of the A3 Adenosine Receptor ((A3AR)) ligand to reduce liver fat particularly in patients with non-alcoholic steatohepatit...
Namodenoson is out-licensed in China for NASH, projected to become $6.4 billion market by 2027 Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, canc...
Clearside Biomedical (CLSD) +52% after positive results from early-stage wet AMD trial.Torchlight Energy Resources (TRCH) +33% after declaring special preferred dividend.Unique Fabricating (UFAB) +29%.Ocugen (OCGN) +20% after securing manufacturing partnership for COVAXIN in th...
Can-Fite BioPharma (CANF) has received clearance from the Israeli Ministry of Health to commence a Phase IIb study of its drug candidate namodenoson in the treatment of non-alcoholic steatohepatitis ((NASH)).The company now expects to commence enrollment in Q3 2021, ahead of the pri...
A prior Phase IIa clinical trial has been successfully concluded and met study end points Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer an...
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
Can-Fite has received agreement from both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) on the current pivotal Phase 3 clinical study Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietar...
ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m. Eastern ...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IN...